MAP2K7 and neoplasm: In line with these results, we found that the replacement of vemurafenib with MEK inhibitors in the triple combination prevented the tumourigenic activity retained by sphere cells (figure 4A, B) and tumour progression when delivered in vivo, as indicated by the decrease in Ki67, CD44v6 and CK20 expression (figure 4C, D and online supplemental figure 4A–C).